Concert Pharmaceuticals, Inc. CNCE
Set alert
8.37 0.00 0.00%
At close · Mar 3
8.35 Day range 8.55
52-week range unavailable
- Open
- 8.38
- Prev close
- 8.37
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.35
- High
- 8.55
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 9, 2023
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 13.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: buy
Buy
Price target (mean) 13.00 +55.3% upside
Now 8.37
- Target (low)
- 9.00
- Target (mean)
- 13.00
- Target (high)
- 17.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 9, 2023
Expected Mar 9, 2023. Consensus EPS estimate -0.63.
Financials — quick view
CNCE Revenue — quarterly 8.00K
CNCE Net income — quarterly -28.90M
CNCE EPS — quarterly -0.58
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 9, 2023 | Dec 1, 2022 | -0.59 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | -0.59 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.90 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.93 | — | — | — |
| Mar 3, 2022 | Dec 1, 2021 | -0.76 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -0.76 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 19, 2023 | JonesTrading | down | Buy | Hold |
| Sep 12, 2022 | Truist Securities | main | — | Buy |
| Aug 24, 2022 | JonesTrading | init | — | Buy |
| Oct 4, 2021 | Mizuho | main | — | Buy |
| Feb 1, 2021 | Truist Securities | main | — | Buy |
| Dec 15, 2020 | Berenberg | init | — | Buy |
News
- Concert Pharmaceuticals: Negative Spread But Interesting CVR
- Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
- Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
- CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
- CNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to Shareholders
- SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
- Concert (CNCE) Stock Up 17% Last Week on Sun Pharma Buyout Offer
- Why Concert Pharmaceuticals Stock Rocketed Higher This Week
- CONCERT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Concert Pharmaceuticals, Inc. - CNCE
- SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.
Your note
Sign in to keep a note on CNCE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALDRICH RICHARD H | Director | Stock Award(Grant) | Jun 8, 2022 | 613,377 |
| AUCHINCLOSS THOMAS G JR | Director | Stock Award(Grant) | Jun 8, 2022 | 34,025 |
| BECKER MARC A | Chief Financial Officer | Sale | Feb 14, 2023 | 123,863 |
| CASSELLA JAMES V | Officer | Sale | Feb 14, 2023 | 173,061 |
| HUTT PETER BARTON | Director | Sale | Oct 13, 2022 | 29,488 |
| JAEGER WILFRED E | Director | Stock Award(Grant) | Jun 8, 2022 | 21,525 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kynam Capital Management, LP | 7.11% | 4,420,349 | 25.81M | Dec 30, 2022 |
| BVF Inc. | 5.83% | 3,629,000 | 21.19M | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 3.07% | 1,910,984 | 11.16M | Dec 30, 2022 |
| Nantahala Capital Management, LLC | 2.78% | 1,732,388 | 10.12M | Dec 30, 2022 |
| Millennium Management Llc | 2.32% | 1,441,735 | 8.42M | Dec 30, 2022 |
| Citadel Advisors Llc | 2.24% | 1,391,302 | 8.13M | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.85% | 1,153,883 | 7.73M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.97% | 604,519 | 4.05M | Sep 29, 2022 |
| iShares NASDAQ Biotechnology ETF | 0.61% | 378,364 | 2.21M | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.34% | 211,131 | 1.02M | Nov 29, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 138,100 | 925.27K | Sep 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.22% | 136,040 | 794.47K | Dec 30, 2022 |